STOCK TITAN

Q/C Technologies: PharmaCyte reports 49.99% ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Q/C Technologies, Inc. (QCLS) amended agreements with PharmaCyte Biotech, Inc., which exchanged 851,304 Series G Long-Term Warrants for 4,982,272 common shares; the shares were delivered November 18, 2026. PharmaCyte also acquired 127,296 shares on July 31 and 42,432 shares on October 1 in connection with Series G dividends, at a valuation of $3.3717 per share, with no additional cash paid.

PharmaCyte reported beneficial ownership of 8,446,093 shares, or 49.99%, including 5,152,000 common shares and 3,294,093 shares acquirable within 60 days through warrant exercise and preferred-stock conversion. The agreements extended the Series H preferred maturity date from March 2, 2027, to September 2, 2027, and limit conversions or warrant exercises that would put PharmaCyte, its affiliates and other aggregated persons above 49.99% ownership.

Shares exchanged for warrants 4,982,272 shares Delivered November 18, 2026, in exchange for 851,304 Series G Long-Term Warrants
Reported beneficial ownership 8,446,093 shares PharmaCyte’s reported aggregate, including shares acquirable within 60 days
Beneficial ownership percentage 49.99% Percentage of class reported by PharmaCyte
Shares acquirable within 60 days 3,294,093 shares Through warrant exercise and conversion of Series G and Series H preferred shares, subject to the ownership limitation
Common shares acquired for Series G dividends 127,296 shares Acquired July 31, 2026, at a valuation of $3.3717 per share
Common shares acquired for Series G dividends 42,432 shares Acquired October 1, 2026, at a valuation of $3.3717 per share
Closing price used in exchange calculation $0.3101 per share Closing price on the last trading day before the Consent Agreement was signed
Common shares outstanding 8,619,201 shares As of November 13, 2026
Series G Long-Term Warrants financial
"851,304 Series G Long-Term Warrants"
Black-Scholes value financial
"equals the Black-Scholes value of the Exchange Warrants"
Beneficial Ownership Limitation regulatory
"Under the amended beneficial ownership limitation provisions"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Series H Maturity Amendment technical
"extending the maturity date of the Series H Preferred Shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many QCLS shares did PharmaCyte receive in the warrant exchange?

PharmaCyte received 4,982,272 common shares in exchange for 851,304 Series G Long-Term Warrants. The shares were delivered November 18, 2026.

What is PharmaCyte’s reported beneficial ownership of QCLS?

PharmaCyte reported 8,446,093 shares, or 49.99%. That amount includes 5,152,000 common shares and 3,294,093 shares acquirable within 60 days through warrant exercise or preferred-stock conversion, subject to the ownership limitation.

When does the QCLS Series H preferred stock maturity date move to?

The maturity date was extended from March 2, 2027, to September 2, 2027 under the Consent and Warrant Exchange Agreement.

What is the QCLS beneficial ownership limit for PharmaCyte?

PharmaCyte may not convert Series G or Series H preferred stock, or exercise Series G Long-Term Warrants, if the action would cause it together with affiliates and other aggregated persons to beneficially own more than 49.99% of QCLS common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





62856X300

(CUSIP Number)
Carlos Trujillo
c/o PharmaCyte Biotech, Inc., 3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV, 89169
(917) 595-2850

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/15/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
The securities consist of (i) 5,152,000 shares of common stock, par value $0.001 per share (the "Common Stock"), of Q/C Technologies, Inc. (the "Issuer"), and (ii) 3,294,093 shares of Common Stock that may be acquired by PharmaCyte Biotech, Inc. (the "Reporting Person") within 60 days upon the exercise of certain warrants and/or the conversion of shares of the Issuer's Series G Convertible Preferred Stock (the "Series G Preferred Shares") and shares of the Issuer's Series H Convertible Preferred Stock (the "Series H Preferred Shares" and, together with the Series G Preferred Shares, the "Preferred Shares"), the exercise and/or conversion of which are subject to the Beneficial Ownership Limitation described in Item 4 hereof. Row 13 is calculated by dividing (i) the number of shares of Common Stock beneficially owned by the Reporting Person by (ii) the sum of (a) 8,619,201 shares of Common Stock outstanding as of November 13, 2026, as reported in the Issuer's Quarterly Report 10-Q, filed with the Securities Exchange Commission on November 16, 2026, (b) 4,982,272 shares of Common Stock issued to the Reporting Person pursuant to the Consent Agreement as described in Item 4 hereof, and (c) 3,294,093 shares of Common Stock that may be acquired by the Reporting Person pursuant to certain warrants and upon the conversion of Preferred Shares.


SCHEDULE 13D


PharmaCyte Biotech, Inc.
Signature:/s/ Carlos Trujillo
Name/Title:Carlos Trujillo, Chief Financial Officer
Date:11/20/2026

Keep reading